[1] Lu Aifen, Zhang Min,.Treatment of 46 Cases of Unstable AnginaPectoris with Yinxing Mihuan Oral Solution Combined with Sodium Tanshinone IIA Sulfonate [J]. Modern Traditional Chinese Medicine, 2019, (06): 58-62. [doi: 10.13424/j.cnki.mtcm.2019.06.018]
Treatment of 46 Cases of Unstable AnginaPectoris with Yinxing Mihuan Oral Solution Combined
with Sodium Tanshinone IIA Sulfonate
- Article number:
- 1672-0571(2019)06-0058-05
- Keywords:
- Yinxing Mihuan Oral Solution; Sodium Tanshinone II A Sulfonate; UAP; hemorheology; vascular hardness
- ZTFLH:
- R541.4
- Code:
- A
- Abstract:
- To explore the clinical effect of Yinxing Mihuan Oral Solution combined with Sodium Tanshinone IIA Sulfonate in the treatment of patients with unstable angina pectoris ( Unstable angina pectoris, UAP) . Methods:Ninety - two UAP patients in Puyang Oilfield General Hospital from June 2016 to October 2018 were selected and randomly divided into treatment group ( n =46) and control group ( n =46) . On the basis of routine treatment, the control group was treated with Sodium Tanshinone IIA Sulfonate, while the treatment group was treated with Yinxing Mihuan Oral Solution combined with Sodium Tanshinone IIA Sulfonate, both for 2 weeks. The clinical and electrocardiographic effects after 2 weeks of treatment were compared with those before treatment. The levels of brachial - ankle pulse wave velocity, plasma hemorheology ( fibrinogen, plasma viscosity, hematocrit) before treatment and 2 weeks after treatment were compared.Results: After 2 weeks of treatment, the clinical and electrocardiographic effects of the treatment group were better than those of the control group ( P < 0. 05) . There was no significant difference in the pulse wave velocity of the ankle and forearm between the two groups ( P > 0. 05) . After 2 weeks of treatment, the pulse wave velocity of the arm and ankle decreased compared with that before treatment, and the treatment group was lower than that of the control group ( P < 0.05) . The levels of albumin, plasma viscosity and hematocrit in the treatment group were lower than those in the control group ( P < 0. 05) . Conclusion: Yinxing Mihuan Oral Solution combined with Sodium Tanshinone II A Sulfonate can reduce vascular hardness and improve hemorheology in patients with unstable angina pectoris.
References:
[1] Zeller T, Keller T, Ojeda F, et al. Assessment of microRNAs in patients with unstable angina pectoris [ J] . Eur Heart J,2014,35( 31) :2106 -2114.
[2]李瑞,樊振.宣痹解毒汤治疗不稳定型心绞痛56例临床研究[J].陕西中医药大学学报,2017,40(3):30-31.
[3] Schlett C L, Jr N J, Schoepf U J, et al. Differences in coronary artery disease by CT angiography between patients developing unstable angina pectoris vs major adverse cardiac events[ J] . Eur J Radiol,2014,83( 7) :1113 -1119.
[4]赵博,王京,宋延斌.丹红注射液对不稳定型心绞痛患者血清炎症因子及血管内皮功能的影响研究[J].辽宁中医药大学学报,2015,17(9):182-184.
[5]张师义,陈少伯,郭卿.丹红注射液联合参松养心胶囊治疗心血瘀阻证不稳定型心绞痛疗效及对血管内皮功能和炎症因子的影响[J].现代中西医结合杂志,2017,26(17):1850-1853.
[6]闫洁,袁森.银杏蜜环口服溶液联合阿司匹林肠溶片和氯吡格雷治疗冠心病心绞痛的疗效观察[J].现代药物与临床,2016,31(10):1575-1578.
[7]庞洲,查赣,许尔凤.丹参多酚酸盐对老年不稳定型心绞痛患者血液流变学及内皮功能的影响[J].实用药物与临床,2014,17(1):38-40.
[8]陈万林,郑广生,杨平,等.远程缺血预适应对心绞痛患者动脉僵硬度和心率变异性的影响[J].临床心血管病杂志,2017,33(11):30-33.
[9]葛均波,徐永健.内科学[M].第8版.北京:人民卫生出版社,2013:361-363.
[10]郑筱萸.中药新药临床研究指导原则[M].中国医药科技出版社,2002:272-273.
[11] Yang X, Xiong X, Yang G, et al. Chinese patent medicine Xuefu Zhuyu capsule for the treatment of unstable angina pectoris: A systematic review of randomized controlled tri
als[ J] . Complement Ther Med,2014,22( 2) :391 -399.
[12]李英杰,张爱清.复方丹参滴丸辅助治疗老年不稳定型心绞痛疗效观察[J].河北医药,2016,38(12):1842-1844.
[13]邵峰,辜裕光,吴华雄.比索洛尔联合丹参酮ⅡA磺酸钠注射液治疗不稳定型心绞痛的临床研究[J].现代药物与临床,2017,32(6):1025-1028.
[14]赵淑君,齐小玲.丹参酮Ⅱa磺酸钠注射液联合银杏叶提取物治疗冠心病心绞痛疗效及安全性分析[J].中国基层医药,2014,21(15):2379-2380.
[15]张爱鹏.大株红景天注射液联合丹参多酚酸盐治疗不稳定型心绞痛的临床研究[J].现代药物与临床,2018,33(7):1594-1598.
[16]范国颖,谢岩,刘文忠.银杏蜜环口服液对不稳定型心绞痛病人CRP?ESOD?PLPO?ELPO的影响[J].中西医结合心脑血管病杂志,2016,14(18):2137-2140.
[17]王雷,刘洁.麝香保心丸联合常规治疗对不稳定型心绞痛患者的疗效及血液流变学的影响[J].中国药师,2014,17(7):1166-1168.
[18]梁华添,杨震.银杏达莫注射液治疗稳定型心绞痛的疗效及其对患者血管硬度和内皮损伤标志物的影响[J].海南医学,2017,28(12):1911-1913.